In-vivo Ventures is an inception fund focused on incubating new technologies from mid-western research universities and creating commercially viable companies based on those technologies. Since its beginning, In-vivo has added three companies to its portfolio. Those companies include: Quadraspec – a proteomics company (now Perfinity Biosciences, Inc), Kylin Therapeutics – an RNAi drug development company, and Sorian – a wind energy company.
• Developed business model to accelerate the commercialization of university based technologies.
• Grew “Angel” network that invested over $20M in In-vivo portfolio companies
• Identified technologies for University “spin-outs” and negotiated licenses and sponsored research agreements.